{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:07:51Z","timestamp":1746331671024,"version":"3.40.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"46","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hebei Provincial Health Commission research fund project","award":["20240091"],"award-info":[{"award-number":["20240091"]}]},{"name":"Hebei Department of Science and Technology","award":["H2022206584"],"award-info":[{"award-number":["H2022206584"]}]},{"name":"Hebei Provincial Health Commission research fund project","award":["20230898"],"award-info":[{"award-number":["20230898"]}]},{"name":"Wu Jieping Foundation","award":["320.6750.2021.02.108"],"award-info":[{"award-number":["320.6750.2021.02.108"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Small-cell undifferentiated carcinoma (SmCC), as an aggressive malignancy, are most commonly arising in lung. Extrapulmonary SmCC is rare. It was reported that SmCC accounts for only 0.1% to 0.2% of colorectal cancers. Currently, no standard treatment regimen is recommended. Here, we presented a case of SmCC from rectum. The patient achieved pathological complete response (pCR) after surgery, which makes us feel gratified, and we are also eager to share this successful case with more peers to provide more references for clinical decision-making.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 32-year-old male patient presented himself to our outpatient clinic with defecation difficulty for more than 1 month in November 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Colonoscopy revealed a rectal mass 4\u2005cm from the anal margin. Pelvic magnetic resonance imaging revealed a mass in the rectal wall, consistent with the appearance of rectal carcinoma. Cancer cell was found after several biopsies and the immunohistochemistry indicated rectal SmCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Considering that the patient is very young and the malignancy of SmCC is very high, our treatment plan is also very cautious. Many literatures were also searched, but the literature on rectal SmCC is few and the prognosis is poor. Subsequently, we combined the treatment principles of rectal cancer and small cell lung cancer to develop an individualized treatment plan for patients. The patient received neoadjuvant chemoradiotherapy (nCRT) (short-course radiotherapy: 25\u2005Gy\/5 fractions, chemotherapy: etoposide\u2005+\u2005nedaplatin) combined with immune checkpoint inhibitors (ICIs) (tislelizumab). Then, the patient received laparoscopic radical transabdominal resection of rectal carcinoma with a temporary stoma on June 27, 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Postoperative pathology showed that there was chronic inflammation in the rectal mucosa without residual cancer, which meant that the patient achieved pCR after nCRT combined with ICIs. On August 15, 2024, the patient returned to our hospital for review, and no signs of recurrence and metastasis were found. By the time this article is submitted, the patient has survived for more than 35 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This is the first to be reported in a rectal SmCC patient who achieved pCR after nCRT combined with ICIs, which may provide supporting data for using this treatment option for rectal SmCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040368","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:02:27Z","timestamp":1732032147000},"page":"e40368","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant chemo-radiotherapy combined with immune checkpoint inhibitors: A case report of rectal small-cell undifferentiated carcinoma achieved pathological complete response"],"prefix":"10.1097","volume":"103","author":[{"given":"Chaoxi","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-9131","authenticated-orcid":false,"given":"Linlin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyin","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanhang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengpeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3837-0266","authenticated-orcid":false,"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1188-y","article-title":"A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992\u20132010.","volume":"15","author":"Dores","year":"2015","journal-title":"BMC Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.2004.09.075","article-title":"Small-cell carcinomas of the gastrointestinal tract: a review.","volume":"22","author":"Brenner","year":"2004","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl_4","key":"R6-20250504","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up.","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"25092520","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency.","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instabilityhigh colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repairdeficient\/microsatellite instability-high metastatic colorectal cancer.","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer.","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.3390\/cancers15174245","article-title":"Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers.","volume":"15","author":"Ros","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study.","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study.","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.","volume":"100","author":"Koopman","year":"2009","journal-title":"Br J Cancer"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/jnci\/djt173","article-title":"Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.","volume":"105","author":"Lochhead","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"`Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1112276","DOI":"10.3389\/fonc.2023.1112276","article-title":"Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer.","volume":"13","author":"Ros","year":"2023","journal-title":"Front Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer.","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years.","volume":"30","author":"Sauer","year":"2012","journal-title":"J Clin Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(09)60484-0","article-title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.","volume":"373","author":"Sebag-Montefiore","year":"2009","journal-title":"Lancet"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.","volume":"345","author":"Kapiteijn","year":"2001","journal-title":"N Engl J Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.0007-1323.2001.01789.x","article-title":"Tumor location and the effects of preoperative radiotherapy in the treatment of rectal cancer.","volume":"88","author":"Holm","year":"2001","journal-title":"Br J Surg"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial.","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy.","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13014-020-01673-6","article-title":"Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.","volume":"15","author":"Shamseddine","year":"2020","journal-title":"Radiat Oncol"},{"issue":"3_suppl","key":"R28-20250504","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2021.39.3_suppl.63","article-title":"Short-course radiotherapy and subsequent CAPOX plus camrelizumab followed by delayed surgery for locally advanced rectal cancer: Short-term results of a phase II trial.","volume":"39","author":"Lin","year":"2021","journal-title":"J Clin Oncol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13014-015-0411-y","article-title":"Radiation therapy improves survival in rectal small cell cancer \u2013 Analysis of Surveillance Epidemiology and End Results (SEER) data.","volume":"10","author":"Modrek","year":"2015","journal-title":"Radiat Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:03:04Z","timestamp":1746320584000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":29,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040368","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}